March 15 (Reuters) - PDL BioPharma Inc:
* Announces conversion rate adjustments to convertible notes
* Says conversion rate for 2012 notes, as adjusted, is 128.318 shares of common
stock per $1,000 principal amount or $7.79 per share
* Says conversion rate for 2023 notes, as adjusted, is 177.1594 shares of
common stock per $1,000 principal amount
* Says conversion rate for the 2012 notes was previously 119.294 shares of
common stock
* Says conversion rate for the 2023 notes was previously 164.7254 shares
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces conversion rate adjustments to convertible notes
* Says conversion rate for 2012 notes, as adjusted, is 128.318 shares of common
stock per $1,000 principal amount or $7.79 per share
* Says conversion rate for 2023 notes, as adjusted, is 177.1594 shares of
common stock per $1,000 principal amount
* Says conversion rate for the 2012 notes was previously 119.294 shares of
common stock
* Says conversion rate for the 2023 notes was previously 164.7254 shares
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
